普瑞巴林联合盐酸吗啡缓释片治疗晚期癌症患者癌性神经痛的效果

Effects of Pregabalin combined with Morphine hydrochloride sustained-release tablets in treatment of neuropathic cancer pain in patients with advanced cancer

目的:探讨普瑞巴林联合盐酸吗啡缓释片治疗晚期癌症患者癌性神经痛(NCP)的效果。方法:选取60例晚期癌症伴NCP患者为研究对象,按照随机数字表法分为对照组和观察组各30例。对照组采用单一盐酸吗啡缓释片治疗,观察组在对照组基础上联合普瑞巴林胶囊治疗。比较两组治疗前后疼痛数字评分法(NRS)评分、睡眠质量[匹兹堡睡眠质量指数(PSQI)]评分,以及不良反应发生率。结果:治疗1、3、7 d后,观察组NRS评分显著低于对照组,差异有统计学意义(P<0.05);治疗7 d后,观察组睡眠质量、入睡时间、睡眠时间、睡眠效率、睡眠障碍、催眠药物、日间功能障碍评分及PSQI总分均显著低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为10.00%(3/30),低于对照组的33.33%(10/30),差异有统计学意义(P<0.05)。结论:普瑞巴林联合盐酸吗啡缓释片用于晚期癌症NCP患者,能有效减轻患者疼痛程度,提高其睡眠质量,降低不良反应发生率,效果优于单用盐酸吗啡缓释片治疗。

Objective: To explore Effects of Pregabalin combined with Morphine hydrochloride sustained-release tablets in treatment of neuropathic cancer pain(NCP) in patients with advanced cancer. Methods: 60 patients with advanced cancer and NCP were selected as the research objects and were divided into control group and observation group according to the random number table method, 30 cases in each group. The control group was treated with single Morphine hydrochloride sustained-release tablets, while the observation group was treated with Pregabalin capsules on the basis of that of the control group. The pain numerical scale(NRS) score, the sleep quality [Pittsburgh sleep quality index(PSQI)] score and the incidence of adverse reactions were compared between the two groups before and after the treatment. Results: After 1, 3, and 7 days of treatment,the NRS scores of the observation group were significantly lower than those of the control group, and the differences were statistically significant(P<0.05). After 7 days of treatment, the sleep quality, the sleep onset time, the sleep time, the sleep efficiency, the sleep disturbance, the hypnotic drugs, the daytime dysfunction score and the total PSQI score in the observation group were significantly lower than those in the control group, and the differences were statistically significant(P<0.05). Further, the incidence of adverse reactions in the observation group was 10.00%(3/30), which was lower than 33.33%(10/30) in the control group, and the difference was statistically significant(P<0.05). Conclusions: Pregabalin combined with Morphine hydrochloride sustained-release tablets for the NCP patients with advanced cancer can effectively reduce their pains, improve their sleep quality, and reduce the incidence of adverse reactions. Moreover, it is superior to single Morphine hydrochloride sustained-release tablets treatment.